News

Press Releases

AOA Dx Inc Signs Exclusive License Agreement with Professor H. Uri Saragovi to Secure a Suite of IP Related To Early Detection of Cancer Through a Novel Quantification of Tumor Ganglioside in Liquid Biopsies

August 2, 2021

AOA Dx Inc Gets Y Combinator’s Backing and Raises $2.5 Million Seed Round to Develop First Non-invasive Ovarian Cancer Liquid Biopsy Diagnostic Test 

June 28, 2021

AOA Dx Inc Announce MassNextGen $87,500 Non-Dilutive Funding from Massachusetts Life Science Center

June 16, 2021

AOA Dx Inc & Prof. Uri Saragovi Awarded $100,000 CAD by the Canadian Institute of Health Research for the Development of Early Stage Ovarian Cancer Diagnostic

May 20, 2021

AOA Dx Inc signs exclusive option agreement to commercialize cancer diagnosis technology from Professor Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University

January 4, 2021

AOA Dx Inc Files US Patent (No. 63,087427) for the identification of gangliosides as markers for ovarian cancer

January 4, 2021

RQRM Grant Awarded to technology licensed by AOA Dx Inc.

Prof. Uri Saragovi and Dr. Anne-Marie Mes-Masson were awarded a grant from the RQRM for initial tumor-ganglioside screening studies to enable early detection of cancers

January 4, 2021

McGill University’s Clinical Innovation Competition supports the development of Prof. Uri Saragovi’s research on ovarian cancer tumour markers. AOA Dx Inc to lead development and commercialization

January 4, 2021

AOA Dx Inc is Proud to Announce Prof. H. Uri Saragovi, Chief Scientific Officer of AOA Dx, Has Been Awarded a $650,000 CAD by the Canadian Institute of Health Research for Further Development of a AKRIVIS GD    Proprietary Liquid Biopsy Test for Diagnosis of Early Stage Ovarian Cancer Diagnosis

August 16, 2021

TM